THOMAS ALEXANDER WALDMANN, M.D.
Osteopathic Medicine at Rickover Rd, Silver Spring, MD

7094404, Aug 22, 2006

Jun 7, 1995

08/478748

Thomas A. Waldmann - Silver Spring MD, US

The United States of America as represented by the Department of Health and Human Services - Washington DC

A61K 39/395

4241541, 4241301, 4241331, 4241381, 4241411, 4241431, 4241441, 4241531, 4241551, 4241561, 4241731, 4241741, 4241781, 4241811, 4241831, 424 149

The present invention relates to a method for treating conditions associated with elevated levels of Tac-positive cells, including malignancy and autoimmune disorders and for preventing allograft rejection. Y-Conjugated anti-Tac or Ricin A conjugated anti-Tac and optionally unconjugated anti-Tac antibodies are employed to treat the above conditions. Clinical therapies have been designed to treat immune diseases and lymphomas in patients using conjugated anti-Tac antibodies.

2004026, Dec 30, 2004

Sep 5, 2003

10/657006

Christine Dingivan - Gaithersburg MD, US
Thomas Waldmann - Silver Spring MD, US
Zhuo Zhang - Clarksburg MD, US

A61K039/395

424/155100

The present invention encompasses the use of a CD2 antagonist, preferably MEDI-507, an analog, derivative or an antigen-binding fragment thereof as a single agent therapy for the prevention, treatment, management, or amelioration of cancer, particularly a T-cell malignancy, or one or more symptoms thereof. The present invention also encompasses the use of a CD2 antagonist, preferably MEDI-507, an analog, derivative or an antigen-binding fragment thereof in combination with other cancer therapies. The present invention provides pharmaceutical compositions comprising a CD2 antagonist, preferably MEDI-507, an analog, derivative or an antigen-binding fragment thereof in amounts effective to prevent, treat, manage, or ameliorate cancer, particularly a T-cell malignancy, or one or more symptoms thereof

2005020, Sep 22, 2005

Dec 6, 2004

11/005575

Thomas Waldmann - Silver Spring MD, US

and Human Services - Rockville MD

A61K051/00

424001490

The present invention relates to a method for treating malignancy and autoimmune disorders and for preventing allograft rejection. Conjugated or unconjugated monoclonal anti-Tac antibodies are employed to treat the above conditions. Clinical therapies have been designed to treat immune diseases and lymphomas in patients using conjugated anti-Tac antibodies.

2006014, Jul 6, 2006

Dec 15, 2003

10/538974

Thomas Waldmann - Silver Spring MD, US
Jay Berzofsky - Bethesda MD, US

GOVERNMENT of the US, as represented by the Secretary , Department of Health and Human Service - Rockville MD

A61K 48/00, C12N 7/00, C12N 15/867

424093200, 435456000, 435235100

The invention is directed to compositions capable of augmenting the immunogenicity of a vaccine. The composition, or adjuvant, is administered to a mammal in need thereof in sequential or concurrent combination with a vaccine antigen. In one preferred aspect, the adjuvant is provided in the form of a recombinant poxvirus vector, such as a vaccinia virus vector, which comprises a nucleic acid sequence encoding IL-15.

7575742, Aug 18, 2009

Nov 27, 2002

10/519311

Roland Martin - Bethesda MD, US
Henry McFarland - Gaithersburg MD, US
Bibiana Bielekova - Kensington MD, US
Thomas Waldmann - Silver Spring MD, US

The United States of America as represented by the Secretary of the Department of Health and Human Services - Washington DC

A61K 38/21, A61K 39/395, C07K 14/00, C07K 16/00

424 854, 4241431, 530351, 53038822

Disclosed is a method of administering an interleukin-2 receptor (IL-2R) antagonist to a subject to treat an autoimmune disease. In particular embodiments, the IL-2R antagonist is an anti-IL-2R monoclonal antibody specific for one or more chains of the IL-2R, such as the alpha-chain, for example daclizumab. In other particular embodiments the autoimmune disease is multiple sclerosis. In certain embodiments administration of interferon-beta is combined with administration of an antagonist of the IL-2R to provide significant clinical improvement in a subject with an autoimmune disease.

8298525, Oct 30, 2012

Mar 10, 2009

12/401543

Roland Martin - Bethesda MD, US
Henry McFarland - Gaithersburg MD, US
Bibiana Bielekova - Kensington MD, US
Thomas Waldmann - Silver Spring MD, US

The United States of America as represented by the Secretary of the Department of Health and Human Services - Washington DC

A61K 38/21, A61K 39/395, A61K 38/20, C07K 14/55, C07K 16/28

424 854, 4241431, 530351, 5303882

Disclosed is a method of administering an interleukin-2 receptor (IL-2R) antagonist to a subject to treat an autoimmune disease. In particular embodiments, the IL-2R antagonist is an anti-IL-2R monoclonal antibody specific for one or more chains of the IL-2R, such as the alpha-chain, for example daclizumab. In other particular embodiments the autoimmune disease is multiple sclerosis. In certain embodiments administration of interferon-beta is combined with administration of an antagonist of the IL-2R to provide significant clinical improvement in a subject with an autoimmune disease.

6051405, Apr 18, 2000

Apr 8, 1992

7/865722

David FitzGerald - Silver Spring MD
Vijay Kumar Chaudhary - Rockville MD
Ira Harry Pastan - Potomac MD
Thomas Alexander Waldmann - Silver Spring MD
Cary L Queen - Palo Alto CA

The United States of America as represented by the Secretary of the
Department of Health and Human Services - Washington DC
Protein Design Labs, Inc. - Fremont CA

C07K 1646

435 697

The present invention describes constructs encoding recombinant scFv-toxin fusion proteins which selectively kill cells bearing appropriate antigens or receptors.

8636997, Jan 28, 2014

Sep 12, 2012

13/612763

Roland Martin - Bethesda MD, US
Henry McFarland - Gaithersburg MD, US
Bibiana Bielekova - Kensington MD, US
Thomas Waldmann - Silver Spring MD, US

The United States of America as represented by the Secretary of the Department of Health and Human Services - Washington DC

A61K 38/21, A61K 39/395, C07K 14/565, C07K 16/28

424 856, 4241441, 530351, 53038822

Disclosed is a method of administering an interleukin-2 receptor (IL-2R) antagonist to a subject to treat an autoimmune disease. In particular embodiments, the IL-2R antagonist is an anti-IL-2R monoclonal antibody specific for one or more chains of the IL-2R, such as the alpha-chain, for example daclizumab. In other particular embodiments the autoimmune disease is multiple sclerosis. In certain embodiments administration of interferon-beta is combined with administration of an antagonist of the IL-2R to provide significant clinical improvement in a subject with an autoimmune disease.

5833983, Nov 10, 1998

Jun 5, 1995

8/463491

Thomas A. Waldmann - Silver Spring MD
Warren J. Leonard - Bethesda MD

The United States of America as represented by the Secretary of Dept. of
Health and Human Services - Washington DC

C07K 1628, C07K 1646, A61K 39395

4241301

The present invention is related to the field of receptor molecules and complexes. More particularly, the present invention is related to a new polypeptide receptor for interleukin-2 having a molecular weight of about 70-75,000, which is a component of the high affinity IL-2 receptor, antibodies against this new polypeptide, and recombinant interleukins capable of binding to the new receptor. Various applications of the p70-75 receptor, the anti-p70-75 antibodies and IL-2W. sub. 1 and IL2W. sub. 2 have also been described.

5696237, Dec 9, 1997

Jun 5, 1995

8/463163

David FitzGerald - Silver Spring MD
Vijay Kumar Chaudhary - Rockville MD
Ira Harry Pastan - Potomac MD
Thomas Alexander Waldmann - Silver Spring MD
Cary L. Queen - Palo Alto CA

The United States of America as represented by the Department of Health
and Human Services - Washington DC

C07K 1646

5303873

The present invention describes recombinant antibody toxin fusion proteins which selectively kill cells bearing appropriate antigens or receptors.